Collectively, these studies suggest that the TGF-β1 T869C polymorphism could serve as a predictive biomarker for RA and other autoimmune diseases, which is crucial for the early diagnosis and personalized treatment strategy development. This evidence concerns the gene TGFB1 and autoimmune disease.